Role of oncogenes, cycline dependant kinase and inhibitors in regulation of cell cycle Robbins based md pathology exam easy to learn and replicate

Reading File

Finding Sources

Searching PubMed

cell cycle AND cancer

Searching the Web

NCBI Bookshelf Robbins Basic Pathology cell cycle cyclins CDK inhibitors oncogenes

Finding Sources

Reading File

Regulation of Cell Cycle: Oncogenes, Cyclins-CDKs, and CDK inhibitors

One-line concept

Cell cycle progression is driven by cyclin-CDK complexes and restrained by CDK inhibitors and tumor-suppressor proteins. Cancer develops when the accelerator is stuck on or the brakes fail.

1. Cell-cycle phases

G0 → G1 → S → G2 → M

G0: resting, non-dividing state
G1: cell growth and preparation for DNA replication
S: DNA synthesis
G2: preparation for mitosis
M: mitosis and cell division

Most important checkpoint for exams: G1/S restriction point

At this checkpoint the cell decides whether to enter S phase and replicate DNA.

Once it passes G1/S, it is largely committed to complete division.

2. Cyclins and CDKs: the accelerator

Cyclins

Regulatory proteins whose levels rise and fall cyclically.
They activate CDKs.

Cyclin-dependent kinases (CDKs)

Enzymes present relatively constantly in cells.
Become active only after binding an appropriate cyclin.
Active cyclin-CDK complexes phosphorylate target proteins and move the cell forward through the cell cycle.

Cyclin decides the timing; CDK performs the action.

High-yield cyclin-CDK pairs

Cell-cycle stage	Cyclin-CDK complex	Main action
Early G1	Cyclin D-CDK4/6	Starts phosphorylation of RB
Late G1 to S	Cyclin E-CDK2	Pushes cell across G1/S checkpoint
S phase	Cyclin A-CDK2	DNA replication
G2 to M	Cyclin B-CDK1	Entry into mitosis

Mnemonic: D-E-A-B = “Drive Every Answer Brilliantly”

D: G1 “Drive”
E: “Entry” into S phase
A: DNA synthesis is “Active”
B: “Beginning” of mitosis

Robbins describes cyclins as sequentially acting regulators, like a relay race, with each cyclin-CDK complex controlling a specific segment of the cycle. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 27.

3. RB protein: the gatekeeper of G1/S checkpoint

In its active form, RB stops cell division

Active RB = hypophosphorylated RB
Active RB binds E2F transcription factors
E2F cannot activate genes needed for DNA synthesis
Therefore, the cell remains in G1 phase

When cyclin-CDK complexes act

Growth-factor signaling increases:

Cyclin D-CDK4/6 and then Cyclin E-CDK2

These complexes phosphorylate RB:

RB phosphorylation → RB becomes inactive → E2F is released → S-phase genes are transcribed → DNA synthesis starts

Easy flowchart to reproduce

Growth factors / oncogenes
          ↓
Cyclin D-CDK4/6 and Cyclin E-CDK2 increase
          ↓
RB is phosphorylated and inactivated
          ↓
E2F is released
          ↓
S-phase genes are expressed
          ↓
G1 → S transition and cell proliferation

Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 277-278.

4. Role of oncogenes: permanent accelerator of proliferation

Proto-oncogenes normally promote controlled growth.
When activated by mutation, amplification, or translocation, they become oncogenes, producing excessive or autonomous cell proliferation.

Major ways oncogenes drive the cell cycle

A. Growth-factor signaling oncogenes

Examples: RAS, EGFR, HER2

They continuously send growth signals even without normal external stimulation.

Oncogene activation
      ↓
RAS/MAPK signaling
      ↓
Increased cyclin D expression
      ↓
Cyclin D-CDK4/6 activation
      ↓
RB inactivation
      ↓
E2F release and entry into S phase

B. MYC oncogene

MYC is a transcription factor stimulated downstream of RAS/MAPK signaling.
It activates genes that promote cell growth and proliferation.
Important targets include cyclin D.
Thus, MYC helps push the cell through G1 toward S phase.

Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 263.

C. Direct cell-cycle oncogenes

Cyclin D overexpression
CDK4 activation/amplification

Both cause excessive phosphorylation of RB and inappropriate G1-to-S progression.

5. CDK inhibitors: the brakes

CDK inhibitors, abbreviated CDKIs, inhibit cyclin-CDK complexes and prevent inappropriate progression through the cell cycle.

Two major families are important.

Family	Important members	Main action
CIP/KIP family	p21, p27, p57	Broad inhibition of several cyclin-CDK complexes
INK4 family	p15, p16, p18, p19	Specifically inhibit CDK4 and CDK6

A. p16/INK4a

Encoded by CDKN2A
Inhibits cyclin D-CDK4/6
Keeps RB in its active, hypophosphorylated form
Therefore, RB continues binding E2F and blocks entry into S phase.

p16 present
    ↓
CDK4/6 inhibited
    ↓
RB remains active
    ↓
E2F remains bound
    ↓
No S phase

In cancer

Loss, deletion, mutation, or silencing of p16 removes this brake.

Loss of p16
    ↓
CDK4/6 becomes active
    ↓
RB hyperphosphorylation
    ↓
E2F release
    ↓
Uncontrolled cell proliferation

Robbins emphasizes that the p16-cyclin D-CDK4-RB pathway is disrupted in most human cancers through alteration of one or more components. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 278.

B. p21: link between p53 and cell-cycle arrest

p21 is a CDK inhibitor induced by p53 after DNA damage.

DNA damage
    ↓
p53 activated
    ↓
p21 synthesis increases
    ↓
Cyclin-CDK complexes inhibited
    ↓
RB remains active
    ↓
G1/S arrest
    ↓
Time for DNA repair

If DNA damage cannot be repaired, p53 may trigger apoptosis or permanent senescence.

Thus:

p53 protects the genome; p21 executes p53-mediated cell-cycle arrest.

Robbins, Cotran & Kumar Pathologic Basis of Disease, pp. 283-284.

C. p27

A broad CDK inhibitor of the CIP/KIP family.
Increased by growth-inhibitory signals, particularly TGF-beta.
Suppresses cyclin-CDK activity and slows proliferation.

6. Integrated exam diagram

                 GROWTH FACTORS / ONCOGENES
                  RAS, MYC, EGFR, HER2
                            ↓
                     ↑ Cyclin D
                            ↓
                    Cyclin D-CDK4/6
                            ↓
      p16 ────────|  RB phosphorylation
                            ↓
              RB inactive (hyperphosphorylated)
                            ↓
                       E2F released
                            ↓
                 S-phase gene transcription
                            ↓
                    G1  →  S progression


DNA damage → p53 → p21 ────────| cyclin-CDK complexes
TGF-beta → p27 ────────────────| cyclin-CDK complexes

7. Short-note answer for an MD pathology exam

Cell-cycle progression is regulated by cyclins, CDKs, CDK inhibitors, and the RB checkpoint. Cyclins bind and activate CDKs, which phosphorylate target proteins required for cell-cycle progression. Cyclin D-CDK4/6 and cyclin E-CDK2 are particularly important at the G1/S transition. These complexes phosphorylate RB protein, causing release of E2F transcription factors, which activate genes needed for DNA synthesis.

Oncogenes such as RAS and MYC promote cell proliferation by increasing growth signaling and cyclin D expression. Direct activation of cyclin D or CDK4 also drives inappropriate RB phosphorylation and uncontrolled entry into S phase.

CDK inhibitors act as negative regulators. The INK4 family, especially p16, inhibits cyclin D-CDK4/6 complexes. The CIP/KIP family, including p21, p27, and p57, inhibits multiple cyclin-CDK complexes. p21 is induced by p53 following DNA damage and produces G1/S arrest, allowing DNA repair. Loss of p16, p53, RB, or other checkpoint regulators permits uncontrolled proliferation and contributes to carcinogenesis.

Final memory line

Oncogenes increase cyclin-CDK activity, cyclin-CDK inactivates RB, E2F enters action, and the cell enters S phase. p16, p21, and p27 stop this process.

Recent systematic reviews retrieved did not provide a finding that changes this core Robbins framework.

This is a shared conversation. Sign in to Orris to start your own chat.